Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? (Q53817138)

20 May 2018

title

Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? (English)

1 reference

20 May 2018

main subject

pancreaticoduodenectomy

0 references

1 reference

O Turrini

1

1 reference

20 May 2018

C M Schmidt

2

1 reference

20 May 2018

J Moreno

3

1 reference

20 May 2018

P Parikh

4

1 reference

20 May 2018

J M Matos

5

1 reference

20 May 2018

M G House

6

1 reference

20 May 2018

N J Zyromski

7

1 reference

20 May 2018

A Nakeeb

8

1 reference

20 May 2018

H A Pitt

9

1 reference

20 May 2018

K D Lillemoe

10

1 reference

20 May 2018

publication date

21 May 2009

1 reference

20 May 2018

Journal of Gastrointestinal Surgery

published in

1 reference

20 May 2018

volume

13

1 reference

20 May 2018

issue

10

1 reference

20 May 2018

page(s)

1791-1797

1 reference

20 May 2018

https://scigraph.springernature.com/pub.10.1007/s11605-009-0916-5

exact match

0 references

cites work

Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-alpha in pancreatic and periampullary cancer: results of a feasibility study

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11605-009-0916-5

CA 19-9 in pancreatic cancer

21 January 2018

1 reference

12 December 2020

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

1 reference

12 December 2020

Clinical usefulness of CA-19-9 in pancreatic carcinoma

1 reference

12 December 2020

Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma

1 reference

12 December 2020

Predicting resectability of pancreatic head cancer with multi-detector CT. Surgical and pathologic correlation.

1 reference

12 December 2020

Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas

1 reference

12 December 2020

Perioperative management of pancreatic cancer

1 reference

12 December 2020

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704

1 reference

12 December 2020

Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms

1 reference

12 December 2020

PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms

1 reference

12 December 2020

A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

1 reference

12 December 2020

CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer

1 reference

12 December 2020

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?

1 reference

12 December 2020

Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy

1 reference

12 December 2020

Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

1 reference

12 December 2020

Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma

1 reference

12 December 2020

Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.

1 reference

12 December 2020

Metastatic pancreatic cancer 2008: is the glass less empty?

1 reference

12 December 2020

Current adjuvant and targeted therapies for pancreatic adenocarcinoma

1 reference

12 December 2020

Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma

1 reference

12 December 2020

Predicting resectability of periampullary cancer with three-dimensional computed tomography

1 reference

12 December 2020

Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9

1 reference

12 December 2020

Pancreatic adenocarcinoma: the actual 5-year survivors

1 reference

12 December 2020

CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent

1 reference

12 December 2020

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma

1 reference

12 December 2020

10.1007/S11605-009-0916-5

Identifiers

DOI

1 reference

20 May 2018

PubMed ID

19459018

1 reference

20 May 2018